24-Hour Crisis Hotline: (877)SAFEGBC or (877)723-3422 Mental Health & Substance Abuse Issues

6502 Nursery Drive, Suite 100
Victoria, TX 77904
(361)575-0611
(800)421-8825
Fax: (361)578-5500

Medical Disorders
Resources
Basic InformationLookupsLatest News
Inflammatory Bowel Disease, Celiac Are Linked: ReviewCOVID-19 Rates May Be Lower Than Thought for Pregnant WomenAs Postponed Surgeries Resume, Can U.S. Hospitals Handle the Strain?Most Americans Still More Worried About COVID-19 Spread Than the EconomyWhat to Know If You're Headed to College With Asthma or AllergiesCoronavirus Was Already Spreading in U.S. in January: StudyAHA News: Inherited High Cholesterol May Be Common in People With Heart DiseaseDVT Clots Strike Many Critically Ill COVID-19 Patients: StudyYour Eyewear and COVID-19 SafetyPandemic Having More Impact on U.S. Hospitals Than Thought: StudyBig Need for Blood Donations as Postponed Surgeries ResumeAs Hard-Hit Areas of America Show Slowing in Coronavirus Cases, Other Regions See SpikesHydroxychloroquine May Worsen Odds for Cancer Patients With COVID-191 in 10 Hospitalized COVID-19 Patients With Diabetes Dies: StudyAHA News: How Bacteria in Your Gut Interact With the Mind and BodyMusic Might Help Soothe Ailing HeartsCould an Injected Electrode Control Your Pain Without Drugs?100,000 Dead, 40 Million Unemployed: America Hits Grim Pandemic MilestonesFDA Approves IV Artesunate for Severe Malaria'Silent' COVID-19 More Widespread Than ThoughtDrug Combos May Be Advance Against Heart FailurePollen Fragments Linger After Rains, Leaving Allergy Sufferers MiserableA New Hip or Knee Can Do a Marriage Good, Study FindsOnly Half of Americans Say They'd Get a Coronavirus Vaccine: SurveyAlzheimer's Gene Linked to Severe COVID-19 RiskCoronavirus Cases Ticking Upwards in Nearly a Dozen U.S. StatesLockdown Got You Down? Experts Offer Tips to De-StressCould a Hormone Help Spur High Blood Pressure?Nursing Homes Are Ground Zero for COVID-19Getting Back to Work Safely After LockdownRemdesivir Will Not Be Enough to Curb COVID-19, Study FindsOutdoor Swimming Pools Not a COVID-19 Risk: ExpertStrokes Are Deadlier When They Hit COVID-19 PatientsAHA News: How to Accurately Measure Blood Pressure at HomeU.S. Earmarks $1.2 Billion for New Vaccine Deal as Coronavirus Deaths Near 95,000During the Pandemic, How Safe Is the Great American Summer Vacation?COVID-19 Damages Lungs Differently From the Flu: StudyMore Evidence Hydroxychloroquine Won't Help, May Harm COVID-19 PatientsYour Sleep Habits May Worsen Your AsthmaExtra Pounds Could Bring More Painful JointsCOVID Can Complicate Pregnancy, Especially If Mom Is ObeseWHO Predicts COVID-19 Will Take Heavy Toll in AfricaCombining Remdesivir With Other Meds Could Boost COVID-Fighting PowerMultiple Sclerosis Ups Odds for Heart Trouble, StrokeAHA News: Not Wanting to Burden Busy Hospitals, She Disregarded Heart Attack SignsExperimental Vaccines Shield Monkeys From CoronavirusHeart Attack Cases at ERs Fall by Half – Are COVID Fears to Blame?Asthma Ups Ventilator Needs of Younger Adults With COVID-19: Study1 in 5 Hospitalized NYC COVID-19 Patients Needed ICU CareObesity Ups Odds for Dangerous Lung Clots in COVID-19 Patients
Questions and AnswersLinks
Related Topics

Diabetes

Xpovio With Dexamethasone Approved for Refractory Multiple Myeloma


HealthDay News
Updated: Jul 10th 2019

new article illustration

TUESDAY, July 9, 2019 (HealthDay News) -- Xpovio (selinexor) tablets have been approved for use in combination with dexamethasone to treat adults with relapsed refractory multiple myeloma, the U.S. Food and Drug Administration announced last week.

The drug combination was granted accelerated approval for patients whose disease remains resistant to other treatments, including at least two proteasome inhibitors, at least two immunomodulatory agents, and an anti-CD38 monoclonal antibody.

Approval was based on data from 83 patients with relapsed refractory multiple myeloma who received Xpovio and dexamethasone. Researchers found an overall response rate of 25.3 percent at the end of the study. Median time to first response was four weeks and ranged from one to 10 weeks. Median response duration was 3.8 months. The FDA notes that approval was also based on information from an ongoing, randomized trial in patients with multiple myeloma, but additional clinical trials are required to verify the clinical benefit of Xpovio.

Commonly reported side effects with the drug combination include leukopenia, low neutrophil count, neutropenia, thrombocytopenia, and anemia. Vomiting, nausea, fatigue, diarrhea, fever, decreased appetite, weight loss, constipation, upper respiratory tract infections, and hyponatremia were also reported. Clinicians should monitor patients being treated with Xpovio and dexamethasone for low blood counts, platelets, and sodium levels; they should optimize patients' hydration status, blood counts, and other medications to avoid dizziness or confusion. Patients should be advised to not take Xpovio with medications that could cause dizziness or confusion.

Approval of Xpovio was granted to Karyopharm Therapeutics.

More Information